Holen Sie sich die Stockscreener-App
4.10
9.09%
-0.41
Handel nachbörslich:
4.17
0.07
+1.71%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAMP?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.51
Offen:
$4.48
24-Stunden-Volumen:
112.99K
Relative Volume:
0.62
Marktkapitalisierung:
$212.90M
Einnahmen:
$3.50M
Nettoeinkommen (Verlust:
$-80.40M
KGV:
-1.5946
EPS:
-2.5711
Netto-Cashflow:
$-29.83M
1W Leistung:
-1.20%
1M Leistung:
-7.66%
6M Leistung:
+13.26%
1J Leistung:
+105.00%
1-Tages-Spanne:
$4.01
$4.63
1-Wochen-Bereich:
$4.01
$4.70
52-Wochen-Spanne:
$1.305
$7.75
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Firmenname
Camp 4 Therapeutics Corp
Sektor
Branche
Telefon
617-651-8867
Adresse
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.10 | 234.19M | 3.50M | -80.40M | -29.83M | -2.5711 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-10-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-27 | Eingeleitet | Wedbush | Outperform |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
| 2022-08-16 | Hochstufung | Craig Hallum | Hold → Buy |
| 2021-12-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2021-09-24 | Bestätigt | Craig Hallum | Buy |
| 2021-06-25 | Bestätigt | Craig Hallum | Buy |
| 2020-12-18 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-04-17 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-05 | Bestätigt | Craig Hallum | Buy |
| 2019-12-20 | Bestätigt | Craig Hallum | Buy |
| 2019-12-20 | Herabstufung | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-01 | Bestätigt | Craig Hallum | Buy |
| 2019-03-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-01-25 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-12-21 | Hochstufung | Craig Hallum | Hold → Buy |
| 2018-12-14 | Bestätigt | B. Riley FBR | Buy |
| 2018-12-11 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | Eingeleitet | Goldman | Neutral |
| 2018-10-15 | Eingeleitet | Jefferies | Hold |
| 2018-09-28 | Bestätigt | Craig Hallum | Hold |
| 2018-04-27 | Bestätigt | Craig Hallum | Hold |
| 2018-03-08 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-02-16 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
Alle ansehen
Camp 4 Therapeutics Corp Aktie (CAMP) Neueste Nachrichten
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
CAMP Technical Analysis | Trend, Signals & Chart Patterns | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill
Camp4 Therapeutics Corp CEO unveils gene expression strategy with regRNA for rare disease therapy - Traders Union
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model - BioWorld News
Balyasny Asset Management (CAMP) reports 2.63M shares; 4.99% warrant blocker - Stock Titan
CAMP4 Therapeutics Reports Preclinical Success of CMP-002 in Reducing Seizures for SYNGAP1-Related Disorder, Plans Phase 1/2 Trial in 2026 - Minichart
CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy - TipRanks
CAMP4 reports positive preclinical seizure data for CMP-002 - Investing.com
Camp4 Therapeutics Corp unveils new preclinical data on SYNGAP1 seizure model in Boston - Traders Union
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder - The Manila Times
CAMP4 Therapeutics to Present New Preclinical Data - GlobeNewswire
Camp4 Therapeutics Corp targets capital discipline with new R and D focus - Traders Union
CAMP4 Therapeutics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Camp4 Therapeutics Corp posts Q1 2026 financial results and reveals corporate developments - Traders Union
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Rare-disease drug moves toward human trial as CAMP4 projects cash into 2028 - Stock Titan
CAMP4 Therapeutics (NASDAQ: CAMP) details Q1 2026 results and cash runway into 2028 - Stock Titan
Camp4 Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CAMP4 Therapeutics (CAMP) posts Q1 2026 loss but keeps cash runway into 2028 - Stock Titan
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Short Interest in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Expands By 13.1% - MarketBeat
Camp4 Therapeutics Corp engages with SYNGAP1 families to inform regRNA therapeutic progress - Traders Union
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation - The Manila Times
CAMP4 maps thousands of new RNAs for gene-boosting drugs - Stock Titan
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
CAMP4 (CAMP) details director votes, auditor ratification and equity plan - Stock Titan
[ARS] Camp4 Therapeutics Corp SEC Filing - Stock Titan
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March - MarketBeat
Three new CAMP4 hires get stock options at $4.59 a share - Stock Titan
Camp4 Therapeutics Corp boosts team engagement with employee event on the slopes - Traders Union
CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw - MarketBeat
CAMP4 (CAMP) Stock: Market Pricing (Drifts Higher) 2026-04-15Community Hot Stocks - Newser
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Australia
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating - Investing.com
CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H - MarketBeat
Life sciences leaders unite at Camp4 Therapeutics Corp-backed event supporting health equity - Traders Union
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Camp4 Therapeutics Corp advances creative strategies in complex drug discovery partnerships - Traders Union
Is CAMP4 (CAMP) Stock Good for Beginners | Price at $4.72, Up 5.59%Trending Momentum Stocks - Newser
Camp4 Therapeutics (CAMP) grants 170,000 stock options to Chief Scientific Officer - Stock Titan
Camp4 Therapeutics (CAMP) CMO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics (CAMP) CFO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics Corp (CAMP) CEO granted 580,000 stock options at $4.46 - Stock Titan
Camp4 Therapeutics (CAMP) director awarded 56,000 stock options at $4.46 strike - Stock Titan
Camp4 Therapeutics (CAMP) director Michael MacLean files initial Form 3 - Stock Titan
Amazon To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
CAMP Stock Analysis: CAMP4 Therapeutics Corporation biotech performance at 4.47 - Newser
Leerink raises CAMP4 Therapeutics price target on CMP-002 progress By Investing.com - Investing.com South Africa
Finanzdaten der Camp 4 Therapeutics Corp-Aktie (CAMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Camp 4 Therapeutics Corp-Aktie (CAMP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Polaris Management Co. VII, L. | 10% Owner |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Nashat Amir | Director |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Maricich Yuri | Chief Medical Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
6,060 |
| Gold Kelly | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
67,877 |
| Mandel-Brehm Josh | Chief Executive Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
278,417 |
| Young Richard A | Director |
Sep 11 '25 |
Buy |
1.65 |
15,151 |
24,999 |
170,010 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):